Dotarizine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Dotarizine
Accession Number
DB06446
Type
Small Molecule
Groups
Investigational
Description
Not Available
Structure
Thumb
Synonyms
Not Available
Categories
UNII
IO7663S6D3
CAS number
84625-59-2
Weight
Average: 442.5925
Monoisotopic: 442.262028342
Chemical Formula
C29H34N2O2
InChI Key
LRMJAFKKJLRDLE-UHFFFAOYSA-N
InChI
InChI=1S/C29H34N2O2/c1-4-11-25(12-5-1)28(26-13-6-2-7-14-26)31-21-19-30(20-22-31)18-10-17-29(32-23-24-33-29)27-15-8-3-9-16-27/h1-9,11-16,28H,10,17-24H2
IUPAC Name
1-(diphenylmethyl)-4-[3-(2-phenyl-1,3-dioxolan-2-yl)propyl]piperazine
SMILES
C(CN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1)CC1(OCCO1)C1=CC=CC=C1

Pharmacology

Indication

Investigated for use/treatment in migraine and cluster headaches.

Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
U5-hydroxytryptamine receptor 2ANot AvailableHuman
U5-hydroxytryptamine receptor 1ANot AvailableHuman
UVoltage-dependent P/Q-type calcium channel subunit alpha-1ANot AvailableHuman
U5-hydroxytryptamine receptor 2CNot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2-HYDROXY-1,4-NAPHTHOQUINONEThe risk or severity of adverse effects can be increased when 2-HYDROXY-1,4-NAPHTHOQUINONE is combined with Dotarizine.Experimental
2-mercaptobenzothiazoleThe risk or severity of adverse effects can be increased when 2-mercaptobenzothiazole is combined with Dotarizine.Vet Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Dotarizine.Approved, Investigational
AmobarbitalThe metabolism of Dotarizine can be increased when combined with Amobarbital.Approved, Illicit
AmorolfineThe risk or severity of adverse effects can be increased when Amorolfine is combined with Dotarizine.Approved, Investigational
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Dotarizine.Approved, Investigational
AnidulafunginThe risk or severity of adverse effects can be increased when Anidulafungin is combined with Dotarizine.Approved, Investigational
ArotinololThe risk or severity of hypotension, conduction block, and bradycardia can be increased when Arotinolol is combined with Dotarizine.Investigational
ArtemetherThe risk or severity of adverse effects can be increased when Artemether is combined with Dotarizine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Dotarizine is combined with Atorvastatin.Approved
AtosibanThe risk or severity of adverse effects can be increased when Dotarizine is combined with Atosiban.Approved, Investigational
Bafilomycin A1The risk or severity of adverse effects can be increased when Bafilomycin A1 is combined with Dotarizine.Experimental
BarbexacloneThe metabolism of Dotarizine can be increased when combined with Barbexaclone.Experimental
BarbitalThe metabolism of Dotarizine can be increased when combined with Barbital.Illicit
Benzoic AcidThe risk or severity of adverse effects can be increased when Benzoic Acid is combined with Dotarizine.Approved
BifonazoleThe risk or severity of adverse effects can be increased when Bifonazole is combined with Dotarizine.Approved, Investigational
Brefeldin AThe risk or severity of adverse effects can be increased when Brefeldin A is combined with Dotarizine.Experimental
BucindololBucindolol may increase the hypotensive activities of Dotarizine.Investigational
BunazosinBunazosin may increase the hypotensive activities of Dotarizine.Investigational
ButenafineThe risk or severity of adverse effects can be increased when Butenafine is combined with Dotarizine.Approved
ButoconazoleThe risk or severity of adverse effects can be increased when Butoconazole is combined with Dotarizine.Approved
Calcium AcetateThe therapeutic efficacy of Dotarizine can be decreased when used in combination with Calcium Acetate.Approved
Calcium CarbonateThe therapeutic efficacy of Dotarizine can be decreased when used in combination with Calcium Carbonate.Approved
Calcium ChlorideThe therapeutic efficacy of Dotarizine can be decreased when used in combination with Calcium Chloride.Approved
Calcium CitrateThe therapeutic efficacy of Dotarizine can be decreased when used in combination with Calcium Citrate.Approved
Calcium glubionateThe therapeutic efficacy of Dotarizine can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Dotarizine can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Dotarizine can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe therapeutic efficacy of Dotarizine can be decreased when used in combination with Calcium lactate.Approved, Experimental, Investigational, Vet Approved
Calcium lactate gluconateThe therapeutic efficacy of Dotarizine can be decreased when used in combination with Calcium lactate gluconate.Experimental
Calcium levulinateThe therapeutic efficacy of Dotarizine can be decreased when used in combination with Calcium laevulate.Approved, Experimental
Calcium pangamateThe therapeutic efficacy of Dotarizine can be decreased when used in combination with Calcium pangamate.Experimental
Calcium PhosphateThe therapeutic efficacy of Dotarizine can be decreased when used in combination with Calcium Phosphate.Approved
CandicidinThe risk or severity of adverse effects can be increased when Candicidin is combined with Dotarizine.Withdrawn
Capric acidThe risk or severity of adverse effects can be increased when Capric acid is combined with Dotarizine.Experimental
CarbomycinThe metabolism of Dotarizine can be decreased when combined with Carbomycin.Vet Approved
CarvedilolCarvedilol may increase the hypotensive activities of Dotarizine.Approved, Investigational
CaseinThe therapeutic efficacy of Dotarizine can be decreased when used in combination with Casein.Approved
CaspofunginThe risk or severity of adverse effects can be increased when Caspofungin is combined with Dotarizine.Approved
CerivastatinThe risk or severity of adverse effects can be increased when Dotarizine is combined with Cerivastatin.Withdrawn
CeruleninThe risk or severity of adverse effects can be increased when Cerulenin is combined with Dotarizine.Approved
ChloroxineThe risk or severity of adverse effects can be increased when Chloroxine is combined with Dotarizine.Approved
CiclopiroxThe risk or severity of adverse effects can be increased when Ciclopirox is combined with Dotarizine.Approved, Investigational
CimetidineThe serum concentration of Dotarizine can be increased when it is combined with Cimetidine.Approved
ClarithromycinThe metabolism of Dotarizine can be decreased when combined with Clarithromycin.Approved
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Dotarizine.Approved
ClotrimazoleThe risk or severity of adverse effects can be increased when Clotrimazole is combined with Dotarizine.Approved, Vet Approved
CordycepinThe risk or severity of adverse effects can be increased when Cordycepin is combined with Dotarizine.Investigational
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Dotarizine.Approved, Investigational, Vet Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Dotarizine.Investigational
DichloropheneThe risk or severity of adverse effects can be increased when Dichlorophene is combined with Dotarizine.Vet Approved
DoxazosinDoxazosin may increase the hypotensive activities of Dotarizine.Approved
EconazoleThe risk or severity of adverse effects can be increased when Econazole is combined with Dotarizine.Approved
EfavirenzThe serum concentration of Dotarizine can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe risk or severity of adverse effects can be increased when Efinaconazole is combined with Dotarizine.Approved
ErythromycinThe metabolism of Dotarizine can be decreased when combined with Erythromycin.Approved, Vet Approved
FenticonazoleThe risk or severity of adverse effects can be increased when Fenticonazole is combined with Dotarizine.Experimental
FluconazoleThe serum concentration of Dotarizine can be increased when it is combined with Fluconazole.Approved
FlucytosineThe risk or severity of adverse effects can be increased when Flucytosine is combined with Dotarizine.Approved
FlutrimazoleThe risk or severity of adverse effects can be increased when Flutrimazole is combined with Dotarizine.Experimental
FluvastatinThe risk or severity of adverse effects can be increased when Dotarizine is combined with Fluvastatin.Approved
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Dotarizine.Approved
GlyphosateThe risk or severity of adverse effects can be increased when Glyphosate is combined with Dotarizine.Experimental
GriseofulvinThe risk or severity of adverse effects can be increased when Griseofulvin is combined with Dotarizine.Approved, Vet Approved
HachimycinThe risk or severity of adverse effects can be increased when Hachimycin is combined with Dotarizine.Experimental
HaloproginThe risk or severity of adverse effects can be increased when Haloprogin is combined with Dotarizine.Approved, Withdrawn
HexetidineThe risk or severity of adverse effects can be increased when Hexetidine is combined with Dotarizine.Approved, Investigational
HexobarbitalThe metabolism of Dotarizine can be increased when combined with Hexobarbital.Approved
IndoraminIndoramin may increase the hypotensive activities of Dotarizine.Withdrawn
IsoconazoleThe risk or severity of adverse effects can be increased when Isoconazole is combined with Dotarizine.Approved
ItraconazoleThe risk or severity of adverse effects can be increased when Itraconazole is combined with Dotarizine.Approved, Investigational
JosamycinThe metabolism of Dotarizine can be decreased when combined with Josamycin.Approved, Investigational
KetoconazoleThe risk or severity of adverse effects can be increased when Ketoconazole is combined with Dotarizine.Approved, Investigational
KitasamycinThe metabolism of Dotarizine can be decreased when combined with Kitasamycin.Experimental
LabetalolLabetalol may increase the hypotensive activities of Dotarizine.Approved
LovastatinThe risk or severity of adverse effects can be increased when Dotarizine is combined with Lovastatin.Approved, Investigational
MepartricinThe risk or severity of adverse effects can be increased when Mepartricin is combined with Dotarizine.Experimental
MethohexitalThe metabolism of Dotarizine can be increased when combined with Methohexital.Approved
MethylphenobarbitalThe metabolism of Dotarizine can be increased when combined with Methylphenobarbital.Approved
MevastatinThe risk or severity of adverse effects can be increased when Mevastatin is combined with Dotarizine.Experimental
MicafunginThe risk or severity of adverse effects can be increased when Micafungin is combined with Dotarizine.Approved, Investigational
MiconazoleThe risk or severity of adverse effects can be increased when Miconazole is combined with Dotarizine.Approved, Investigational, Vet Approved
MiltefosineThe risk or severity of adverse effects can be increased when Miltefosine is combined with Dotarizine.Approved
MonensinThe risk or severity of adverse effects can be increased when Monensin is combined with Dotarizine.Vet Approved
MyxothiazolThe risk or severity of adverse effects can be increased when Myxothiazol is combined with Dotarizine.Experimental
NafcillinThe metabolism of Dotarizine can be increased when combined with Nafcillin.Approved
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Dotarizine.Approved
NatamycinThe risk or severity of adverse effects can be increased when Natamycin is combined with Dotarizine.Approved
NifuratelThe risk or severity of adverse effects can be increased when Nifuratel is combined with Dotarizine.Experimental
Nikkomycin ZThe risk or severity of adverse effects can be increased when Nikkomycin Z is combined with Dotarizine.Investigational
NitroprussideDotarizine may increase the hypotensive activities of Nitroprusside.Approved
NitroxolineThe risk or severity of adverse effects can be increased when Nitroxoline is combined with Dotarizine.Approved
NystatinThe risk or severity of adverse effects can be increased when Nystatin is combined with Dotarizine.Approved, Vet Approved
OleandomycinThe metabolism of Dotarizine can be decreased when combined with Oleandomycin.Vet Approved
OmoconazoleThe risk or severity of adverse effects can be increased when Omoconazole is combined with Dotarizine.Experimental
OxiconazoleThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Dotarizine.Approved
PafuramidineThe risk or severity of adverse effects can be increased when Pafuramidine is combined with Dotarizine.Investigational
PentamidineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Dotarizine.Approved
PentobarbitalThe metabolism of Dotarizine can be increased when combined with Pentobarbital.Approved, Vet Approved
PhenobarbitalThe metabolism of Dotarizine can be increased when combined with Phenobarbital.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Dotarizine.Approved, Vet Approved
PitavastatinThe risk or severity of adverse effects can be increased when Dotarizine is combined with Pitavastatin.Approved
PosaconazoleThe risk or severity of adverse effects can be increased when Posaconazole is combined with Dotarizine.Approved, Investigational, Vet Approved
PravastatinThe risk or severity of adverse effects can be increased when Dotarizine is combined with Pravastatin.Approved
PrazosinPrazosin may increase the hypotensive activities of Dotarizine.Approved
PrimidoneThe metabolism of Dotarizine can be increased when combined with Primidone.Approved, Vet Approved
PyrrolnitrinThe risk or severity of adverse effects can be increased when Pyrrolnitrin is combined with Dotarizine.Experimental
RadicicolThe risk or severity of adverse effects can be increased when Radicicol is combined with Dotarizine.Experimental
RifabutinThe serum concentration of Dotarizine can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Dotarizine can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Dotarizine can be decreased when it is combined with Rifapentine.Approved
RifaximinThe serum concentration of Dotarizine can be decreased when it is combined with Rifaximin.Approved, Investigational
RosuvastatinThe risk or severity of adverse effects can be increased when Dotarizine is combined with Rosuvastatin.Approved
Salicylhydroxamic AcidThe risk or severity of adverse effects can be increased when Salicylhydroxamic Acid is combined with Dotarizine.Experimental
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Dotarizine.Approved, Vet Approved
SecobarbitalThe metabolism of Dotarizine can be increased when combined with Secobarbital.Approved, Vet Approved
SertaconazoleThe risk or severity of adverse effects can be increased when Sertaconazole is combined with Dotarizine.Approved
SilodosinSilodosin may increase the hypotensive activities of Dotarizine.Approved
SimvastatinThe risk or severity of adverse effects can be increased when Dotarizine is combined with Simvastatin.Approved
SinefunginThe risk or severity of adverse effects can be increased when Sinefungin is combined with Dotarizine.Experimental
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Dotarizine.Approved, Investigational
SolithromycinThe metabolism of Dotarizine can be decreased when combined with Solithromycin.Investigational
SulconazoleThe risk or severity of adverse effects can be increased when Sulconazole is combined with Dotarizine.Approved
TamsulosinTamsulosin may increase the hypotensive activities of Dotarizine.Approved, Investigational
TavaboroleThe risk or severity of adverse effects can be increased when Tavaborole is combined with Dotarizine.Approved
TelithromycinThe metabolism of Dotarizine can be decreased when combined with Telithromycin.Approved
TerazosinTerazosin may increase the hypotensive activities of Dotarizine.Approved
TerbinafineThe risk or severity of adverse effects can be increased when Terbinafine is combined with Dotarizine.Approved, Investigational, Vet Approved
TerconazoleThe risk or severity of adverse effects can be increased when Terconazole is combined with Dotarizine.Approved
ThiamylalThe metabolism of Dotarizine can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Dotarizine can be increased when combined with Thiopental.Approved, Vet Approved
ThymolThe risk or severity of adverse effects can be increased when Thymol is combined with Dotarizine.Approved
TioconazoleThe risk or severity of adverse effects can be increased when Tioconazole is combined with Dotarizine.Approved
TolciclateThe risk or severity of adverse effects can be increased when Tolciclate is combined with Dotarizine.Experimental
TolnaftateThe risk or severity of adverse effects can be increased when Tolnaftate is combined with Dotarizine.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Dotarizine.Experimental
TrimetrexateThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Dotarizine.Approved, Investigational
TylosinThe metabolism of Dotarizine can be decreased when combined with Tylosin.Vet Approved
UbidecarenoneThe risk or severity of adverse effects can be increased when Dotarizine is combined with Ubidecarenone.Approved, Investigational, Nutraceutical
UrapidilUrapidil may increase the hypotensive activities of Dotarizine.Investigational
VoriconazoleThe risk or severity of adverse effects can be increased when Voriconazole is combined with Dotarizine.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
55285
ChemSpider
49929
ChEBI
138033
ChEMBL
CHEMBL2106316
Wikipedia
Dotarizine

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00339 mg/mLALOGPS
logP4.62ALOGPS
logP5.91ChemAxon
logS-5.1ALOGPS
pKa (Strongest Basic)8.62ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area24.94 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity134.13 m3·mol-1ChemAxon
Polarizability51.47 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9661
Blood Brain Barrier+0.9869
Caco-2 permeable+0.5
P-glycoprotein substrateSubstrate0.5606
P-glycoprotein inhibitor INon-inhibitor0.5661
P-glycoprotein inhibitor IINon-inhibitor0.7562
Renal organic cation transporterInhibitor0.6695
CYP450 2C9 substrateNon-substrate0.8982
CYP450 2D6 substrateNon-substrate0.6457
CYP450 3A4 substrateNon-substrate0.6014
CYP450 1A2 substrateNon-inhibitor0.6406
CYP450 2C9 inhibitorNon-inhibitor0.7607
CYP450 2D6 inhibitorNon-inhibitor0.5786
CYP450 2C19 inhibitorNon-inhibitor0.7097
CYP450 3A4 inhibitorNon-inhibitor0.8237
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6342
Ames testNon AMES toxic0.7679
CarcinogenicityNon-carcinogens0.926
BiodegradationNot ready biodegradable0.9929
Rat acute toxicity3.0172 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8214
hERG inhibition (predictor II)Non-inhibitor0.5385
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Diphenylmethanes
Direct Parent
Diphenylmethanes
Alternative Parents
Phenylbutylamines / N-alkylpiperazines / Ketals / Aralkylamines / 1,3-dioxolanes / Trialkylamines / Oxacyclic compounds / Azacyclic compounds / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Diphenylmethane / Phenylbutylamine / Ketal / N-alkylpiperazine / Aralkylamine / 1,4-diazinane / Piperazine / Meta-dioxolane / Tertiary amine / Tertiary aliphatic amine
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name
HTR2A
Uniprot ID
P28223
Uniprot Name
5-hydroxytryptamine receptor 2A
Molecular Weight
52602.58 Da
References
  1. Belcheva S, Petkov VD, Konstantinova E, Petkov VV, Boyanova E: Effects on nociception of the Ca2+ and 5-HT antagonist dotarizine and other 5-HT receptor agonists and antagonists. Acta Physiol Pharmacol Bulg. 1995;21(4):93-8. [PubMed:8830881]
  2. Farre M, Roset PN, Llorente M, Marquez M, Albet C, Perez JA, Herrero E, Ortiz JA: Clinical pharmacokinetics and tolerability of dotarizine in healthy subjects after single and multiple oral administration. Methods Find Exp Clin Pharmacol. 1997 Jun;19(5):343-50. [PubMed:9379783]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers...
Gene Name
HTR1A
Uniprot ID
P08908
Uniprot Name
5-hydroxytryptamine receptor 1A
Molecular Weight
46106.335 Da
References
  1. Belcheva S, Petkov VD, Konstantinova E, Petkov VV, Boyanova E: Effects on nociception of the Ca2+ and 5-HT antagonist dotarizine and other 5-HT receptor agonists and antagonists. Acta Physiol Pharmacol Bulg. 1995;21(4):93-8. [PubMed:8830881]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1A
Uniprot ID
O00555
Uniprot Name
Voltage-dependent P/Q-type calcium channel subunit alpha-1A
Molecular Weight
282362.39 Da
References
  1. Ruiz-Nuno A, Mayorgas I, Hernandez-Guijo JM, Olivares R, Garcia AG, Gandia L: Antimigraine dotarizine blocks P/Q Ca2+ channels and exocytosis in a voltage-dependent manner in chromaffin cells. Eur J Pharmacol. 2003 Nov 14;481(1):41-50. [PubMed:14637173]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-...
Gene Name
HTR2C
Uniprot ID
P28335
Uniprot Name
5-hydroxytryptamine receptor 2C
Molecular Weight
51820.705 Da
References
  1. Farre M, Roset PN, Llorente M, Marquez M, Albet C, Perez JA, Herrero E, Ortiz JA: Clinical pharmacokinetics and tolerability of dotarizine in healthy subjects after single and multiple oral administration. Methods Find Exp Clin Pharmacol. 1997 Jun;19(5):343-50. [PubMed:9379783]

Drug created on March 19, 2008 10:33 / Updated on January 05, 2018 16:03